UNSPSC 51141565: Losigamone

This classification denotes an anticonvulsant agent with the molecular formula C12H11ClO4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 84R8O3QM2G, chemically known as 2(5h)-furanone, 5-((2-chlorophenyl)hydroxymethyl)-4-methoxy-, (r*,s*)- but generally known as losigamone, which bears US NIH Compound Identifier 60572. European Medicines Agency schedules Losigamone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08594MIG.

UNSPSC 51141565 Losigamone is a Commodity code for a specific pharmaceutical product, though recent state and local procurement activity under this code does not align with the abstract code designation. The recent opportunities tagged to this code reflect broader pharmaceutical and medical product procurement across multiple categories—from individual drug dispensing systems to multi-state generic pharmaceutical cooperative contracts—rather than losigamone-specific buying. State and local governments posting under this code are soliciting naloxone and drug deactivation systems for community health and harm-reduction initiatives, direct-to-manufacturer prescription program design and fulfillment, and participation in multi-state cooperative purchasing agreements for generic drugs and over-the-counter products. The issuing bodies span county health departments, state health and human services agencies, and multi-state cooperative purchasing alliances that aggregate demand across state and local members.

Recent activity includes Seminole County, Florida's IFB for 1,900 units of naloxone and 800 safe drug deactivation systems annually (response deadline July 26, 2023, with quarterly deliveries required); the Texas Health and Human Services Commission's RFI on implementing a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program (posted April 3, 2026); and the Minnesota Multistate Cooperative Purchasing Alliance's RFP for generic multi-source pharmaceuticals and OTC products with authorized wholesaler distribution (response deadline March 26, 2026, effective July 1, 2026). Geographic activity clusters in Florida, Texas, Minnesota, and participating states in cooperative purchasing arrangements. The Minnesota MMCAP contract requires manufacturers to maintain relationships with at least two of three authorized wholesalers (AmerisourceBergen/Cencora, Cardinal Health, Morris & Dickson), certify cGMP and Drug Supply Chain Security Act compliance, and accept a 3 percent administrative fee on all purchases. The mismatch between the code name and actual procurement activity suggests this code may be misapplied in state and local systems, or the code itself reflects a narrower product line than current buying patterns support.